Listenly

What assumption about biosimilars entering the market is often incorrect when designing benefit programs?

Answered at 21:30 in AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast

— questions searchable right now

What assumption about biosimilars entering the market is often incorrect when designing benefit programs?

A common assumption is that biosimilars are always lower cost than the reference drug. However, while biosimilars have dropped reference drug costs and benefited patients, at the current time the reference drug may actually be significantly lower cost than the biosimilar. Plan sponsors must analyze current pricing to determine the actual lowest-cost option rather than relying on this assumption.

Brian Cotter on The Astonishing Healthcare PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

A common assumption is that biosimilars are always lower cost than the reference drug.

Brian Cotter, Founder at Bright Spot Insights · AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast · answer at 21:30

Key takeaways

  • A common assumption is that biosimilars are always lower cost than the reference drug.

Quote to remember

“Assume the data is incorrect until proven otherwise. You need to work through the steps to validate the data before you can start digging in and understanding what price variation you see.”

— Brian Cotter

The full answer · about 2 min

A common assumption is that biosimilars are always lower cost than the reference drug. However, while biosimilars have dropped reference drug costs and benefited patients, at the current time the reference drug may actually be significantly lower cost than the biosimilar. Plan sponsors must analyze current pricing to determine the actual lowest-cost option rather than relying on this assumption.

Key facts

  • Oxaliplatin ASP price dropped from $2,053 in 2012 to $9.40 in Q1 2026—a 99% reduction
  • One hospital listed oxaliplatin at $29,595 compared to Medicare reimbursement under $10
  • Specialty drug spend now represents 55-60% of pharmacy spend
  • Pharmacy spend represents 25-30% of total plan spend
  • 431 drugs had price drops between Q1 2025 and Q1 2026, with drops up to 99%

People, companies and topics mentioned

Bright Spot InsightsMedicareASP (Average Sales Price)J code (J9263 for oxaliplatin/Eloxatin)Oxaliplatin (Eloxatan)Specialty drugs (oncology)Price transparency dataMedical benefit

More answers from this episode

 ·  All answers from The Astonishing Healthcare Podcast →
—
—
0:00
0:00